Janssen Collaborates with SpringWorks to Evaluate Nirogacestat + Teclistamab for Relapsed or Refractory Multiple Myeloma

 Janssen Collaborates with SpringWorks to Evaluate Nirogacestat + Teclistamab for Relapsed or Refractory Multiple Myeloma

Shots:

  • The companies will evaluate SpringWorks’ Nirogacestat (GSI) in combination with Janssen’s Teclistamab (Ab targeting BCMA and CD3) in patients with r/r MM. The companies anticipate commencing the study by early 2021
  • Janssen to sponsor and conduct a P-I study assessing the safety, tolerability, and preliminary efficacy of the combination, and will assume all costs associated with the study, other than expenses related to the manufacturing of nirogacestat
  • SpringWorks will form a joint oversight committee with Janssen and is currently conducting a global P-III DeFi trial assessing nirogacestat vs PBO in adults with progressing desmoid tumors. Additionally, SpringWorks has entered two other clinical collaborations to evaluate nirogacestat in combination with GSK’s Blenrep (belantamab mafodotin-blmf) and with Allogene’s ALLO-715

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post